WO2012158591A1 - Anti-blepharitis products and methods - Google Patents
Anti-blepharitis products and methods Download PDFInfo
- Publication number
- WO2012158591A1 WO2012158591A1 PCT/US2012/037724 US2012037724W WO2012158591A1 WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1 US 2012037724 W US2012037724 W US 2012037724W WO 2012158591 A1 WO2012158591 A1 WO 2012158591A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- phase
- weight
- blepharitis
- shale oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the disclosure relates generally to the field of products that can prevent or treat blepharitis. More specifically, the present disclosure is directed to preventing or treating blepharitis through application of various cosmetics.
- Blepharitis is one of the most common ocular disorders, affecting millions of Americans. Blepharitis is a continuum of inflammatory disease processes of the eyelid and can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis is inflammation around the eyelashes and follicles, while posterior type involves the meibomian glands. The
- pathophysiology of blepharitis involves bacterial colonization of the eyelids. This bacterial colonization results in immune mediated inflammatory damage to the surrounding tissues.
- formulations of cosmetics that can be used to treat or prevent blepharitis. Further, what is desired are formulations that have anti-bacterial and antiinflammatory effects that can be used as cosmetics.
- Embodiments of the present application provide products and methods that address the above and other issues.
- the present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis.
- the process is directed towards a cosmetic composition comprising verbascoside and a shale oil.
- the present disclosure is also directed to a method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
- the present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
- compositions of the present disclosure provide improvements over traditional cosmetics that cause or exacerbate blepharitis symptoms.
- the improvements are, inter alia, treatment or prevention of blepharitis symptoms and blepharitis through application of the described cosmetic compositions.
- Various cosmetic compositions are disclosed herein.
- Each cosmetic composition includes both 2-(3',4'-dihydroxyphenyl)ethyl-0-a-l-rhamnopyranosyl-(l ⁇ 3)- -d-(4-0- caffeoyl)-glucopyranoside (Verbascoside), also known as kusaginin or acetoside, and a shale oil, among other components.
- These other components can include one or more cosmetically suitable excipients such as glycerine and xantham gum.
- These other components comprise the balance of the total composition as further illustrated among the several examples below, with their individual concentrations depending on the kind of cosmetic composition being produced. Individual concentrations of the suitable excipients are listed in the examples, but these individual concentrations may be modified in either direction, higher or lower percentage, as needed.
- the shale oil can be any shale oil suitable for topical use including light-colored pale sulfonated shale oil (ICHTHYOL® pale) and dark sulfonated shale oil (ICHTHYOL®).
- the shale oil can be present in concentrations ranging from 0.0001% by weight to about 10% by weight of the total composition.
- the shale oil is useful as an anti-inflammatory, anti -bacterial and antimycotic when applied topically and is also water soluble.
- the other components can include a metal ion carrier that can contain any suitable metal ion that is capable of offering and anti-inflammatory or anti-bacterial effect.
- the inorganic metal ion carrier can be an inorganic silver ion carrier.
- the inorganic silver ion carrier can be Ionpure® WP A glass powder, among others.
- Ionpure® is an inorganic, soluble glass containing anti-bacterial metal ions.
- the Ionpure® glass particles are non- volatile, heat resistant and in the presence of water or moisture, will release the metal ions gradually.
- Metal ions, such as silver ions, are taken into microbes where they react, bond and inhibit the microbe's enzyme activity and can reduce multiplication of the microbes. These microbes can include blepharitis causing bacteria.
- the other components can also include glycerophosphoinositol (GPI) lysine.
- GPI Lysine such as Distinctive® GPI Lysine offered by Resources of Nature, Inc. South Plainfield, New Jersey, is useful as an anti-inflammatory and anti-itch substance.
- GPI lysine is stable over a broad range of temperatures and pH's and can be present in concentrations ranging from
- Verbascoside is an effective cellular protectant that can be applied topically.
- Verbascoside can be isolated or extracted from various raw materials.
- verbascoside can be gathered from the leaves of the buddleja cordata tree. The leaves can be dried, ground and extracted with hexane and methanol. The methanolic portion is evaporated to obtain a crude syrup that is further treated to produce a verbascoside amorphous powder.
- Verbascoside is a phenylpropanoid glycoside (PPG) that is a water soluble derivative of phenylpropanoid (PP).
- PPG phenylpropanoid glycoside
- PP phenylpropanoid
- Verbascoside has a strong anti-inflammatory and anti-bacterial activity.
- Distinctive® Phytostem Lilac is one example of a material containing verbascoside, but any other suitable verbascoside containing material could also be used.
- Distinctive® Phytostem Lilac is a cell culture extract titrated in verbascoside.
- the verbascoside and shale oil can be encapsulated, the shale oil and the GPI lysine can also be encapsulated.
- the encapsulated materials can be immediate, sustained or a mixture of immediate and sustained release encapsulations.
- the materials can be encapsulated in any suitable manner, such as the encapsulation methods described in European Patent EP0966268 and those described in "Drug Delivery: Principles and Applications" by Wang, et al. (John Wiley & Sons, Inc. 2005), both of which are incorporated by reference.
- the verbascoside and the inorganic metal ion carrier can be differing concentrations based on the desired result.
- the verbascoside can be about 0.0001% by weight to about 10% by weight of the composition and the inorganic metal ion carrier can be about 0.0001% by weight to about 10% by weight.
- the cosmetic composition can be one of many cosmetic compositions, which can include lotions, creams, eye pencils, eye shadows, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray. These cosmetic compositions can be applied topically on any exposed skin surface that could be affected by blepharitis including, but not limited to, eye lids and the areas surrounding each of the eyes. These cosmetic compositions can be formed using various manufacturing techniques, some of which are described throughout the examples below. Blepharitis can have many different causes, including but not limited to Staphococyl, Seborrheaic, Allergies, Lice, cosmetic products and others from other sources other than cosmetic products.
- the disclosure also includes a method for preventing or treating blepharitis that includes administering a therapeutic amount of verbascoside and shale oil.
- the administration of the verbascoside and shale oil is useful in both preventing the presence of blepharitis and blepharitis symptoms, it is also useful in treating the severity of the blepharitis and blepharitis symptoms such as the reduction of sebum production, reduction of bacterial growth and the unclogging of skin's pores.
- the combination of verbascoside and shale oil provides improved blepharitis prevention and treatment as compared to the administration of verbascoside alone or shale oil alone.
- the combination can be synergistic, e.g., where the joint action of two or more components is such that the combined effect is greater than the sum of their individual effects.
- ICHTHYOL® pale is included.
- lonpure® WPA glass powder can also be used, instead of or in combination with ICHTHYOL® pale, in similar percentages by weight.
- composition is an oil in water lotion:
- the oil in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D and E ingredients are then added.
- composition is an oil in water cream:
- the oil in water cream is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase D, E and F ingredients are then added.
- composition is water in oil lotion:
- Salicylic Acid (as 0.1% to applicable) 20%
- the water in oil lotion is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
- composition is water in oil cream:
- the water in oil cream is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
- composition is for an eye pencil "A":
- the eye pencil "A” is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
- composition is for an eye pencil "B":
- the eye pencil "B" is formed by combining all components of Phase A and heating the mixture to 95 °C. After heating, the mixture is mixed until uniform and cooled to room temperature. The mixture is then formed into a suitable shape for application to a user's eye.
- composition is for an eye shadow:
- composition is for a silicon in water lotion:
- the silicon in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerin and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
- composition is for a water in silicone lotion:
- the water in silicone lotion is formed by first preparing phase A by adding Butylene glycol, glycerin, sodium chloride and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
- composition is for a hydroalcoholic liquid or spray:
- the hydroalcoholic liquid or spray is formed by first preparing phase A by combining all Phase A components. Next, the Phase B, C, D and E components are mixed together and combined with the Phase A components. [0043] In the following example, the composition is for a cosmetic primer:
- Cosmetic primer is formed by first preparing phase A by combining all Phase A components. Next, the Phase E, F and G components are mixed together and combined with the Phase A components. owing example, the composition is for a cosmetic serum:
- the cosmetic serum is formed by first preparing phase A by adding Butylene glycol, glycerin, glyceryl acrylate/acrylic acid copolymer and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
- composition is for a mascara:
- Camauba Wax (Copernicia Cerifera (Carnauba) Wax) 5.00
- Salicylic Acid 0.1% to 20%
- Phase C Retinol or Retinol derivatives 0.01% to 0.25%
- Distinctive® Phytostem Lilac 50 (Maltodextrin (and) Syringa Vulgaris
- Colorants qs [0048] All percentages above are based on weight.
- the cosmetic serum is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
- composition is for a waterproof mascara:
- Waterproof mascara is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye. [0051] In the following example, the composition is for an eyeliner containing iron oxide
- Eyeliner containing iron oxide is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
- composition is for an eyeliner:
- Eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
- Example 17
- composition is for an anhydrous eyeliner:
- Anhydrous eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
- composition is for a mascara containing iron oxide:
- the mascara containing iron oxide is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
- composition is for a single phase cosmetic liquid or spray:
- a single phase cosmetic liquid or spray is formed by first preparing phase A by combining all Phase A components. The components are mixed until uniform, and added to the Phase B, C, D and E components.
- composition is for a wet wipe cloth and liquid:
Abstract
The present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis. The process is directed towards a cosmetic composition including verbascoside and a shale oil. The present disclosure is also directed to a method for preventing blepharitis including administering a therapeutic amount of verbascoside and a shale oil. The present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
Description
ANTI-BLEPHARITIS PRODUCTS AND METHODS
FIELD OF THE DISCLOSURE
[0001] The disclosure relates generally to the field of products that can prevent or treat blepharitis. More specifically, the present disclosure is directed to preventing or treating blepharitis through application of various cosmetics.
BACKGROUND OF THE DISCLOSURE
[0002] Blepharitis is one of the most common ocular disorders, affecting millions of Americans. Blepharitis is a continuum of inflammatory disease processes of the eyelid and can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis is inflammation around the eyelashes and follicles, while posterior type involves the meibomian glands. The
pathophysiology of blepharitis involves bacterial colonization of the eyelids. This bacterial colonization results in immune mediated inflammatory damage to the surrounding tissues.
[0003] People with blepharitis typically present with various complaints including burning, watery eyes, foreign body sensation, red eye lids, red eyes, pain and blurry vision. Physical examination of patients with blepharitis often shows loss of lashes, plugging of the meibomian glands and injection of the conjunctiva. Also, the irritation that blepharitis causes can often lead to dry eyes. If the blepharitis is severe enough it may even affect the cornea, causing marginal infiltrates, marginal ulcers and pannus formation.
[0004] Ophthalmologists often see female patients wearing heavy cosmetics, complaining of symptoms of blepharitis. In these situations, even though the patients are advised to stop
wearing the cosmetics, patients typically refuse to stop wearing cosmetics because they like how the cosmetics make them appear.
[0005] What is desired are formulations of cosmetics that can be used to treat or prevent blepharitis. Further, what is desired are formulations that have anti-bacterial and antiinflammatory effects that can be used as cosmetics.
[0006] Embodiments of the present application provide products and methods that address the above and other issues.
SUMMARY OF THE DISCLOSURE
[0007] The present disclosure is directed to a cosmetic composition and methods for treating or preventing blepharitis. The process is directed towards a cosmetic composition comprising verbascoside and a shale oil.
[0008] The present disclosure is also directed to a method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
[0009] The present disclosure is also directed to a method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0010] The methods and compositions of the present disclosure provide improvements over traditional cosmetics that cause or exacerbate blepharitis symptoms. The improvements are, inter alia, treatment or prevention of blepharitis symptoms and blepharitis through application of the described cosmetic compositions.
[0011] Various cosmetic compositions are disclosed herein. Each cosmetic composition includes both 2-(3',4'-dihydroxyphenyl)ethyl-0-a-l-rhamnopyranosyl-(l→3)- -d-(4-0- caffeoyl)-glucopyranoside (Verbascoside), also known as kusaginin or acetoside, and a shale oil, among other components. These other components can include one or more cosmetically suitable excipients such as glycerine and xantham gum. These other components comprise the balance of the total composition as further illustrated among the several examples below, with their individual concentrations depending on the kind of cosmetic composition being produced. Individual concentrations of the suitable excipients are listed in the examples, but these individual concentrations may be modified in either direction, higher or lower percentage, as needed.
[0012] The shale oil can be any shale oil suitable for topical use including light-colored pale sulfonated shale oil (ICHTHYOL® pale) and dark sulfonated shale oil (ICHTHYOL®). The shale oil can be present in concentrations ranging from 0.0001% by weight to about 10% by weight of the total composition. The shale oil is useful as an anti-inflammatory, anti -bacterial and antimycotic when applied topically and is also water soluble. The other components can include a metal ion carrier that can contain any suitable metal ion that is capable of offering and anti-inflammatory or anti-bacterial effect. As one option, the inorganic metal ion carrier can be an inorganic silver ion carrier. The inorganic silver ion carrier can be Ionpure® WP A glass powder, among others. Ionpure® is an inorganic, soluble glass containing anti-bacterial metal ions. The Ionpure® glass particles are non- volatile, heat resistant and in the presence of water or moisture, will release the metal ions gradually. Metal ions, such as silver ions, are taken into
microbes where they react, bond and inhibit the microbe's enzyme activity and can reduce multiplication of the microbes. These microbes can include blepharitis causing bacteria.
[0013] The other components can also include glycerophosphoinositol (GPI) lysine. GPI Lysine, such as Distinctive® GPI Lysine offered by Resources of Nature, Inc. South Plainfield, New Jersey, is useful as an anti-inflammatory and anti-itch substance. GPI lysine is stable over a broad range of temperatures and pH's and can be present in concentrations ranging from
0.0001% by weight to about 10% by weight of the total composition.
[0014] Verbascoside is an effective cellular protectant that can be applied topically.
Verbascoside can be isolated or extracted from various raw materials. In one example, verbascoside can be gathered from the leaves of the buddleja cordata tree. The leaves can be dried, ground and extracted with hexane and methanol. The methanolic portion is evaporated to obtain a crude syrup that is further treated to produce a verbascoside amorphous powder.
[0015] Verbascoside is a phenylpropanoid glycoside (PPG) that is a water soluble derivative of phenylpropanoid (PP). Verbascoside has a strong anti-inflammatory and anti-bacterial activity. Distinctive® Phytostem Lilac is one example of a material containing verbascoside, but any other suitable verbascoside containing material could also be used. Distinctive® Phytostem Lilac is a cell culture extract titrated in verbascoside.
[0016] The verbascoside and shale oil can be encapsulated, the shale oil and the GPI lysine can also be encapsulated. The encapsulated materials can be immediate, sustained or a mixture of immediate and sustained release encapsulations. The materials can be encapsulated in any suitable manner, such as the encapsulation methods described in European Patent EP0966268
and those described in "Drug Delivery: Principles and Applications" by Wang, et al. (John Wiley & Sons, Inc. 2005), both of which are incorporated by reference.
[0017] In the cosmetic composition, the verbascoside and the inorganic metal ion carrier can be differing concentrations based on the desired result. In the cosmetic composition, the verbascoside can be about 0.0001% by weight to about 10% by weight of the composition and the inorganic metal ion carrier can be about 0.0001% by weight to about 10% by weight.
[0018] The cosmetic composition can be one of many cosmetic compositions, which can include lotions, creams, eye pencils, eye shadows, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray. These cosmetic compositions can be applied topically on any exposed skin surface that could be affected by blepharitis including, but not limited to, eye lids and the areas surrounding each of the eyes. These cosmetic compositions can be formed using various manufacturing techniques, some of which are described throughout the examples below. Blepharitis can have many different causes, including but not limited to Staphococyl, Seborrheaic, Allergies, Lice, cosmetic products and others from other sources other than cosmetic products.
[0019] The disclosure also includes a method for preventing or treating blepharitis that includes administering a therapeutic amount of verbascoside and shale oil. The administration of the verbascoside and shale oil is useful in both preventing the presence of blepharitis and blepharitis symptoms, it is also useful in treating the severity of the blepharitis and blepharitis symptoms such as the reduction of sebum production, reduction of bacterial growth and the unclogging of skin's pores.
[0020] Surprisingly, the combination of verbascoside and shale oil provides improved blepharitis prevention and treatment as compared to the administration of verbascoside alone or shale oil alone. The combination can be synergistic, e.g., where the joint action of two or more components is such that the combined effect is greater than the sum of their individual effects.
[0021] The following examples serve to illustrate aspects of the disclosure but are not intended to limit the scope of the disclosure, which is defined by the claims appended hereto.
EXAMPLES
[0022] For each of the examples below, ICHTHYOL® pale is included. For each of the examples, lonpure® WPA glass powder can also be used, instead of or in combination with ICHTHYOL® pale, in similar percentages by weight.
Example 1
[0023] In the following example, the composition is an oil in water lotion:
E Preservative qs
[0024] All percentages above are based on weight. The oil in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D and E ingredients are then added.
example, the composition is an oil in water cream:
[0026] All percentages above are based on weight. The oil in water cream is formed by first preparing phase A by adding Butylene glycol, glycerine and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase D, E and F ingredients are then added.
Example 3
[0027] In the following example, the composition is water in oil lotion:
Ingredient %(w/w)
Phase
A Deionized Water qs
1,3 Butylene Glycol 5.00
Glycerine 3.00
Disodium EDTA 0.10
Sodium Chloride 2.00
Sodium Borate 0.15
Glycolic Acid or Lactic 2% to
Acid 10%
(as applicable)
Phase
B Mineral Oil 70 vis. 10.00
Petrolatum 4.00
Cetyl Alcohol 2.00
Behenyl Alcohol 1.00
Beeswax 2.50
Dimethicone (350 cks) 1.00
PEG 100 Stearate 3.00
Salicylic Acid (as 0.1% to applicable) 20%
Sorbitan Sesquioleate 0.80
Tocopheryl Acetate 0.50
Phase Distinctive® Phytostem
C Lilac 50 (Maltodextrin
(and) Syringa Vulgaris
(Lilac) Leaf Cell Culture
Extract 0.50
Sodium Sulfonated Shale
Oil 1.00
Retinol or Retinol 0.01% to derivatives 0.25%
(as applicable)
Phase
D Fragrance qs
Phase
E Preservative qs
Phase
F Colorants qs
[0028] All percentages above are based on weight. The water in oil lotion is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 4
[0029] In the following example, the composition is water in oil cream:
[0030] All percentages above are based on weight. The water in oil cream is formed by first preparing phase A by adding Butylene glycol, glycerine, sodium chloride, sodium borate and disodium EDTA to water and the other components, the combination is then heated to 80 °C.
Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 5
[0031] In the following example, the composition is for an eye pencil "A":
[0032] All percentages above are based on weight. The eye pencil "A" is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
Example 6
[0033] In the following example, the composition is for an eye pencil "B":
[0034] All percentages above are based on weight. The eye pencil "B" is formed by combining all components of Phase A and heating the mixture to 95 °C. After heating, the mixture is mixed
until uniform and cooled to room temperature. The mixture is then formed into a suitable shape for application to a user's eye.
[0035] In the following example, the composition is for an eye shadow:
[0036] All percentages above are based on weight. The eye shadow is formed by mixing all components of Phase A together until uniform and forming the mixed components into a suitable shape for application to a user's eye.
Example 8
[0037] In the following example, the composition is for a silicon in water lotion:
[0038] All percentages above are based on weight. The silicon in water lotion is formed by first preparing phase A by adding Butylene glycol, glycerin and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 9
[0039] In the following example, the composition is for a water in silicone lotion:
Ingredient %(w/w)
Phase
A Deionized Water Qs
1,3 Butylene Glycol 5.00
Glycerin 3.00
Glycolic Acid or Lactic Acid 2% to
(as applicable) 10%
Disodium EDTA 0.10
Sodium Chloride 2.00
Phase
B Cyclopentasiloxane 25.00
Polysilicone-11 6.00
Cetyldimethicone Copolyol 1.50
Phenyl Dimethicone 5.00
Ethylhexyl Palmitate 5.00
0.1% to
Salicylic Acid (as applicable) 20%
Phenyl Dimethicone 20.00
Tocopheryl Acetate 0.50
Cetyl Alcohol 2.00
Behenyl Alcohol 1.00
Dimethicone (350 cks) 3.00
Sorbitan Sesquioleate 0.80
Phase
C Distinctive® Phytostem Lilac 50
(Maltodextrin (and) Syringa Vulgaris
(Lilac) Leaf Cell Culture Extract 0.50
Sodium Sulfonated Shale Oil 1.00
Retinol or Retinol derivatives 0.01%
(as applicable) to
0.25%
Phase
D Fragrance Qs
Phase
E Preservative Qs
Phase
F Colorants Qs
[0040] All percentages above are based on weight. The water in silicone lotion is formed by first preparing phase A by adding Butylene glycol, glycerin, sodium chloride and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E and F ingredients are then added.
Example 10
[0041] In the following example, the composition is for a hydroalcoholic liquid or spray:
[0042] All percentages above are based on weight. The hydroalcoholic liquid or spray is formed by first preparing phase A by combining all Phase A components. Next, the Phase B, C, D and E components are mixed together and combined with the Phase A components.
[0043] In the following example, the composition is for a cosmetic primer:
[0044] All percentages above are based on weight. Cosmetic primer is formed by first preparing phase A by combining all Phase A components. Next, the Phase E, F and G components are mixed together and combined with the Phase A components.
owing example, the composition is for a cosmetic serum:
Ingredient %(w/w)
Phase
A Deionized Water qs
1,3 Butylene Glycol 5.00
Glyceryl Acrylate/Acrylic Acid Copolymer 5.00
Glycerin 5.00
Disodium EDTA 0.10
Allantoin 0.25
Xanthan Gum 0.30
Glycolic Acid or Lactic Acid 2% to
(as applicable) 10%
Phase
B Ethylhexyl Palmitate 10.00
Isononyl Isononanoate 4.00
Cetyl Alcohol 1.00
Behenyl Alcohol 1.00
Dimethicone (350 cks) 1.00
Phospholipids 3.00
Hydrogenated Lecithin 2.00
Laureth 4 1.00
0.1% to
Salicylic Acid (as applicable) 20%
PEG 100 Stearate 3.00
Polysorbate 20 0.80
Phase Retinol or Retinol derivatives 0.01%
C (as applicable) to
0.25%
Vitamin E Acetate 1.00
Phase Distinctive® Phytostem Lilac 50 (Maltodextrin
D (and) Syringa Vulgaris (Lilac) Leaf Cell Culture
Extract 0.50
Sodium Sulfonated Shale Oil 1.00
Phase
E Fragrance qs
Phase
F Preservative qs
Phase
G Colorants qs
[0046] All percentages above are based on weight. The cosmetic serum is formed by first preparing phase A by adding Butylene glycol, glycerin, glyceryl acrylate/acrylic acid copolymer and disodium EDTA to water and the other components, the combination is then heated to 80 °C. Next, the Phase B ingredients are mixed together and heated to 80 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 13
[0047] In the following example, the composition is for a mascara:
Ingredient %(w/ )
Phase A Deionized Water qs
Hydroxyethylcellulose 0.75
Distinctive Ink Black Chip AQ (D&C Black #2 (and) Polyester-5 (and)
PVP (and) Laureth-4) 6.00
DC Instalift Lengthening (Water (and) PVP (and) Triticum vulgare
(Wheat) Protein (and) Gossypium Herbaceum (Cotton)) 5.00
DC Hydroglide (Glycerin (and) Water (and) Glycine Soja (Soybean)
Germ Extract (and) Beta Vulgaris (Beet) Root Extract (and) Algae
Extract (and) Sodium Hyaluronate 3.00
Tromethamine 40% 5.69
Preservative q.s.
Glycolic Acid or Lactic Acid 2% to 10% (as applicable)
Phase B Glyceryl Stearate 4.00
Camauba Wax (Copernicia Cerifera (Carnauba) Wax) 5.00
Stearic Acid 4.00
Propylene Glycol Stearate 2.00
Beeswax 4.00
CI 8-36 Triglyceride 0.40
Paraffin Wax (Paraffin) 1.00
Salicylic Acid (as applicable) 0.1% to 20%
Phase C Retinol or Retinol derivatives 0.01% to 0.25%
(as applicable)
Phase D Acrylates Copolymer 10.00
Phase E DC Silica Beads (Silica) 2.00
Distinctive® Phytostem Lilac 50 (Maltodextrin (and) Syringa Vulgaris
(Lilac) Leaf Cell Culture Extract 0.50
DI Water 4.00
Phase F Sodium Sulfonated Shale Oil 1.00
Phase G Fragrance qs
Colorants qs
[0048] All percentages above are based on weight. The cosmetic serum is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 14
[0049] In the following example, the composition is for a waterproof mascara:
[0050] All percentages above are based on weight. Waterproof mascara is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
[0051] In the following example, the composition is for an eyeliner containing iron oxide
[0052] All percentages above are based on weight. Eyeliner containing iron oxide is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
Example 16
[0053] In the following example, the composition is for an eyeliner:
[0054] All percentages above are based on weight. Eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 85 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
Example 17
[0055] In the following example, the composition is for an anhydrous eyeliner:
[0056] All percentages above are based on weight. Anhydrous eyeliner is formed by first preparing phase A by combining all Phase A components and heating them to 95 °C. The components are mixed until uniform, cooled to room temperature and formed into a suitable shape for application to a user's eye.
Example 18
[0057] In the following example, the composition is for a mascara containing iron oxide:
[0058] All percentages above are based on weight. The mascara containing iron oxide is formed by first preparing phase A by adding all the components, the combination is then heated to 85 °C. Next, the Phase B ingredients are mixed together and heated to 85-90 °C. Phase B is added to Phase A while mixing. The entire mixture is cooled to 35 °C while being mixed. Phase C, D, E, F and G components are then added.
Example 19
[0059] In the following example, the composition is for a single phase cosmetic liquid or spray:
[0060] All percentages above are based on weight. A single phase cosmetic liquid or spray is formed by first preparing phase A by combining all Phase A components. The components are mixed until uniform, and added to the Phase B, C, D and E components.
Example 20
[0061] In the following example, the composition is for a wet wipe cloth and liquid:
[0062] All percentages above are based on weight. The wet wipe and liquid are formed by combining phase A ingredients and mixing until uniform. Phase B ingredients are then added and mixed until uniform.
Claims
1. A cosmetic composition comprising verbascoside and a shale oil.
2. The composition of claim 1, further comprising one or more cosmetically suitable excipients.
3. The composition of claim 1, wherein the shale oil is ICHTHYOL® pale.
4. The composition of claim 1, further comprising an inorganic metal ion carrier.
5. The composition of claim 4, wherein the inorganic metal ion carrier is an inorganic silver ion carrier.
6. The composition of claim 5, wherein the inorganic silver ion carrier is a glass containing silver ions.
7. The composition of claim 6, wherein the glass containing silver ions is silver borosilicate.
8. The composition of claim 1, wherein the composition comprises a lotion, cream, eye pencil, eye shadow, hydroalcoholic liquid or spray, primer, serum, mascara, eye liner and a single phase liquid or spray.
9. The composition of claim 1, wherein the verbascoside comprises from about 0.0001% by weight to about 10% by weight of the composition and shale oil comprises from about 0.0001% by weight to about 10% by weight.
10. The composition of claim 1, wherein the shale oil comprises from about 0.0001% by weight to about 10% by weight of the composition.
11. The composition of claim 1, further comprising glycerophosphomositol (GPI) lysine.
12. The composition of claim 10, wherein the GPI lysine comprises from about 0.0001% by weight to about 10% by weight of the composition.
13. A method for preventing blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
14. A method for treating blepharitis comprising administering a therapeutic amount of verbascoside and a shale oil.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161487430P | 2011-05-18 | 2011-05-18 | |
US61/487,430 | 2011-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012158591A1 true WO2012158591A1 (en) | 2012-11-22 |
Family
ID=47177293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/037724 WO2012158591A1 (en) | 2011-05-18 | 2012-05-14 | Anti-blepharitis products and methods |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012158591A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20130763A1 (en) * | 2013-05-09 | 2014-11-10 | Altergon Sa | MONODOSE AND MULTIDOSE TOPIC PREPARATIONS FOR THE TREATMENT OF INFLAMMATORY STATES OF MUCOSE AND SKIN |
WO2016000663A1 (en) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells |
US9642887B1 (en) * | 2015-12-28 | 2017-05-09 | Shetal Amit Shah | Anti-blepharitis compositions and their use |
IT202100028220A1 (en) * | 2021-11-05 | 2023-05-05 | Novax Pharma Sam | Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102289A1 (en) * | 2000-11-30 | 2002-08-01 | Anja Drucks | Cosmetic or dermatological impregnated wipes |
US20050031547A1 (en) * | 2003-08-04 | 2005-02-10 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7625883B1 (en) * | 2000-11-07 | 2009-12-01 | I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. | Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase |
US20100086502A1 (en) * | 2008-10-08 | 2010-04-08 | L'oreal | Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor |
US7718199B2 (en) * | 2005-06-20 | 2010-05-18 | I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. | Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use |
-
2012
- 2012-05-14 WO PCT/US2012/037724 patent/WO2012158591A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625883B1 (en) * | 2000-11-07 | 2009-12-01 | I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. | Glycerophosphoinositol derivatives as modulators of cytosolic A2 phospholipase |
US20020102289A1 (en) * | 2000-11-30 | 2002-08-01 | Anja Drucks | Cosmetic or dermatological impregnated wipes |
US20050031547A1 (en) * | 2003-08-04 | 2005-02-10 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7718199B2 (en) * | 2005-06-20 | 2010-05-18 | I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. | Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use |
US20100086502A1 (en) * | 2008-10-08 | 2010-04-08 | L'oreal | Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20130763A1 (en) * | 2013-05-09 | 2014-11-10 | Altergon Sa | MONODOSE AND MULTIDOSE TOPIC PREPARATIONS FOR THE TREATMENT OF INFLAMMATORY STATES OF MUCOSE AND SKIN |
WO2014180565A1 (en) * | 2013-05-09 | 2014-11-13 | Altergon S.A. | Topical preparations comprising hyaluronic acid, verbascoside and glycerophosphoinositol |
US20160113960A1 (en) * | 2013-05-09 | 2016-04-28 | Altergon S.A. | Topical preparations comprising hyaluronic acid, verbascoside and glycerophosphoinositol |
WO2016000663A1 (en) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells |
US10967029B2 (en) | 2014-07-03 | 2021-04-06 | Sinphar Pharmaceutical Co., Ltd. | Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress |
US9642887B1 (en) * | 2015-12-28 | 2017-05-09 | Shetal Amit Shah | Anti-blepharitis compositions and their use |
EP3187186A1 (en) * | 2015-12-28 | 2017-07-05 | Shetal Amit Shah | Anti-blepharitis compositions and their use |
IT202100028220A1 (en) * | 2021-11-05 | 2023-05-05 | Novax Pharma Sam | Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject |
WO2023079520A1 (en) | 2021-11-05 | 2023-05-11 | Novax Pharma Sam | Ophthalmic composition comprising a lubricant agent and verbascoside, and use of said composition for the preventive or curative treatment of a corneal epithelial defect and/or a conjunctival defect in a subject |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI353861B (en) | ||
US20060165644A1 (en) | Cosmetics | |
CN109431873B (en) | Composition for repairing and relieving skin inflammation | |
KR101425031B1 (en) | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil | |
US20140106009A1 (en) | Methods and compositions for maintaining and improving the health of skin | |
TW201940187A (en) | Topical skin care compositions | |
WO2012158591A1 (en) | Anti-blepharitis products and methods | |
US9642887B1 (en) | Anti-blepharitis compositions and their use | |
JP3556595B2 (en) | Cosmetic composition for skin protection containing retinol and epidermal growth factor | |
KR20200073970A (en) | Soothing cream and manufacturing method for the same | |
KR102300581B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
EP2983684B1 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations | |
CN103494737A (en) | Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation | |
KR20170092281A (en) | Cosmetic Composition for Improving Acnes Using Chamomile | |
WO2014094377A1 (en) | Bee venom composition with effects of protecting and beautifying lip | |
KR101418366B1 (en) | Composition containing bee venom and propolis for preventing or treating acne | |
KR20070011939A (en) | Cosmetic material including extract of camellia flower for skin abirritation | |
EP3378475B1 (en) | Composition and kit for the use in the prevention of recurrent onychomycosis | |
WO2016033899A1 (en) | Dandruff removing composition for adjusting scalp oil balance | |
CN107875079B (en) | Fat-particle-removing essence and preparation method thereof | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
KR101773390B1 (en) | Cosmetic composition for improving acne | |
KR102410642B1 (en) | Hypoallergenic composition for perming eyelashes | |
KR102113866B1 (en) | Cosmetic composition comprising extract of centella asiatica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12786016 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12786016 Country of ref document: EP Kind code of ref document: A1 |